Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.270
+0.010 (0.79%)
At close: Oct 28, 2025, 4:00 PM EDT
1.260
-0.010 (-0.79%)
After-hours: Oct 28, 2025, 7:46 PM EDT
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $1.16M in the quarter ending June 30, 2025, with 19.16% growth. This brings the company's revenue in the last twelve months to $4.36M, up 14.74% year-over-year. In the year 2024, Lucid Diagnostics had annual revenue of $4.35M with 79.00% growth.
Revenue (ttm)
$4.36M
Revenue Growth
+14.74%
P/S Ratio
20.16
Revenue / Employee
$60,556
Employees
72
Market Cap
165.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.35M | 1.92M | 79.00% |
| Dec 31, 2023 | 2.43M | 2.05M | 544.03% |
| Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
LUCD News
- 13 days ago - Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Announces Closing of Public Offering of Common Stock - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - PRNewsWire
- 7 weeks ago - Lucid Diagnostics Announces Proposed Public Offering of Common Stock - PRNewsWire
- 7 weeks ago - Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript) - Seeking Alpha
- 7 weeks ago - Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 - PRNewsWire